Golestan University of Medical Sciences Repository

A2B adenosine receptor agonist induces cell cycle arrest and apoptosis in breast cancer stem cells via ERK1/2 phosphorylation

Jafari, S.M. and Joshaghani, H.R. and Panjehpour, M. and Aghaei, M. (2018) A2B adenosine receptor agonist induces cell cycle arrest and apoptosis in breast cancer stem cells via ERK1/2 phosphorylation. Cellular Oncology, 41 (1). pp. 61-72.

Full text not available from this repository.

Abstract

Purpose: It has been reported that cancer stem cells (CSCs) may play a crucial role in the development, recurrence and metastasis of breast cancer. Targeting signaling pathways in CSCs is considered to be a promising strategy for the treatment of cancer. Here, we investigated the role of the A2B adenosine receptor (A2BAR) and its associated signaling pathways in governing the proliferation and viability of breast cancer cell line derived CSCs. Methods: CSCs were isolated from the breast cancer cell lines MCF-7 and MDA-MB-231 using a mammosphere assay. The effect of the A2BAR agonist BAY606583 on cell proliferation was evaluated using XTT and mammosphere formation assays, respectively. Apoptosis was assessed using Annexin-V staining and cell cycle analyses were performed using flow cytometry. The expression levels of Bax, Bcl-2, cyclin-D1, CDK-4 and (phosphorylated) ERK1/2 were assessed using Western blotting. Results: Our data revealed that the breast cancer cell line derived mammospheres were enriched for CSCs. We also found that A2BAR stimulation with its agonist BAY606583 inhibited mammosphere formation and CSC viability. In addition, we found that the application of BAY606583 led to CSC cell cycle arrest and apoptosis through the cyclin-D1/Cdk-4 and Bax/Bcl-2 pathways, respectively. Notably, we found that BAY606583 significantly down-regulated ERK1/2 phosphorylation in the breast cancer cell line derived CSCs. Conclusions: From our results we conclude that A2BAR induces breast CSC cell cycle arrest and apoptosis through downregulation of the ERK1/2 cascade. As such, A2BAR may be considered as a novel target for the treatment of breast cancer. © 2017, International Society for Cellular Oncology.

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: adenosine A2 receptor agonist; bay 606583; caspase 6; cell surface marker; cyclin D1; cyclin dependent kinase 4; mitogen activated protein kinase 1; octamer transcription factor 4; protein Bax; protein bcl 2; transcription factor Sox2; unclassified drug, apoptosis; Article; breast cancer; cell cycle arrest; cell viability; cell viability assay; controlled study; flow cytometry; human; human cell; MCF-7 cell line; MDA-MB-231 cell line; mRNA expression level; priority journal; protein expression; protein phosphorylation; reverse transcription polymerase chain reaction
Subjects: مقالات نمایه شده محققین دانشگاه در سایت ,Web of Science ,Scopus
Divisions: UNSPECIFIED
Depositing User: GOUMS
Date Deposited: 16 Apr 2018 05:37
Last Modified: 16 Apr 2018 05:37
URI: http://eprints.goums.ac.ir/id/eprint/9563

Actions (login required)

View Item View Item